BSLN Share Price Performance
CHF 53.60
15.25 (39.77%)
Price CHF 53.60
Share PriceCHF 53.60
BSLN Community Narratives
There are no narratives available yet.
Recent BSLN News & Updates
No updates
Basilea Pharmaceutica AG Key Details
Last Reported Earnings
Dec 31, 2024
Next Reporting Earnings
Aug 19, 2025
- Earnings per share (EPS)
- 6.32
- Gross Margin
- 44.46%
- Net Profit Margin
- 37.21%
- Debt/Equity Ratio
- 118.4%
Basilea Pharmaceutica AG Competitors
About BSLN
- Founded
- 2000
- Employees
- 164
- CEO
- WebsiteView website
Basilea Pharmaceutica AG engages in the discovering, developing, and commercializing drugs for bacterial or fungal infections. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis. It also develops Fosmanogepix, an antifungal drug for the treatment of Candidemia, which is in Phase II clinical trials; BAL2062 for invasive mold infections, which is in Phase I of clinical trials; and BAL2420, an antibiotics to treat severe Enterobacteriaceae infections. In addition, the company provides Zevtera, an antibiotic for the treatment of pneumonia, as well as develop for the treatment of Staphylococcus aureus bacteremia, acute bacterial skin, and skin structure infections. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.
Swiss Market Performance
- 7 Days: -1.5%
- 3 Months: -1.5%
- 1 Year: 0.2%
- Year to Date: 1.5%
Over the last 7 days, the market has dropped 1.5%, driven by a decline of 3.9% in the Healthcare sector. In the last 12 months the market has been flat overall. Looking forward, earnings are forecast to grow by 11% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading